Literature DB >> 33598792

Sarcoid-like reaction in cases treated by checkpoint inhibitors.

Semra Paydas1.   

Abstract

Sarcoidosis is a multisystem granulomatous disorder characterized by helper T cell inflammation. Sarcoid-like reaction (SLR) is a well-defined entity and may be related with several malignant disorders and/or their therapies. SLR has been reported more than 20 years ago and in recent years in cases treated by checkpoint inhibitors (CPIs). Better outcome has been reported in cases developing granulomatous reaction and/or SLRs during CPI treatments. However, these lesions clinically may be thought as disease progression and may cause to stop treatment or alterations. These therapeutic manipulations may be harmful for the patients. Clinicians should be aware of SLRs in cases treated by CPIs and tissues must be sampled and reviewed by an experienced pathologist to avoid misdiagnosis and also unnecessary CPI treatment cessations.Significance StatementClinicians should be aware of sarcoid-like reactions in cases treated by checkpoint inhibitors and tissues must be sampled and reviewed by an experienced pathologist to avoid misdiagnosis and CPI treatment stops.

Entities:  

Keywords:  Checkpoint inhibitor; Clinical outcome; Sarcoid-like reaction

Year:  2021        PMID: 33598792     DOI: 10.1007/s12032-021-01477-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  43 in total

1.  Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis.

Authors:  Bregje Ten Berge; Marthe S Paats; Ingrid M Bergen; Bernt van den Blink; Henk C Hoogsteden; Bart N Lambrecht; Rudi W Hendriks; Alex Kleinjan
Journal:  Rheumatology (Oxford)       Date:  2011-11-10       Impact factor: 7.580

2.  Granulomatous reaction after chemotherapy for Hodgkin's disease.

Authors:  Semra Paydas; Sinan Yavuz; Umut Disel; Handan Zeren; Serap Hastürk; Ismail Hanta; Melek Ergin; Berksoy Sahin
Journal:  Leuk Res       Date:  2002-10       Impact factor: 3.156

3.  Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient.

Authors:  A Eckert; A Schoeffler; S Dalle; A Phan; L Kiakouama; L Thomas
Journal:  Dermatology       Date:  2008-10-02       Impact factor: 5.366

4.  Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

Authors:  J M Naccache; M Antoine; M Wislez; J Fleury-Feith; E Oksenhendler; C Mayaud; J Cadranel
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

5.  Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.

Authors:  Sree Harsha Tirumani; Nikhil H Ramaiya; Abhishek Keraliya; Nancy D Bailey; Patrick A Ott; F Stephen Hodi; Mizuki Nishino
Journal:  Cancer Immunol Res       Date:  2015-06-22       Impact factor: 11.151

6.  Sarcoidosis is a Th1/Th17 multisystem disorder.

Authors:  Monica Facco; Anna Cabrelle; Antonella Teramo; Valeria Olivieri; Marianna Gnoato; Sara Teolato; Elisa Ave; Cristina Gattazzo; Gian Paolo Fadini; Fiorella Calabrese; Gianpietro Semenzato; Carlo Agostini
Journal:  Thorax       Date:  2010-12-07       Impact factor: 9.139

7.  Bacillus Calmette-Guérin therapy-associated granulomatous prostatitis mimicking prostate cancer on MRI: A case report and literature review.

Authors:  Nicolaie Suditu; Dragos Negru
Journal:  Mol Clin Oncol       Date:  2014-09-19

8.  A Rare Case of Granulomatous Pneumonitis Due to Intravesical BCG for Bladder Cancer.

Authors:  Vera Clérigo; Ana Castro; Teresa Mourato; Conceição Gomes
Journal:  Acta Med Port       Date:  2019-04-30

Review 9.  Sarcoidosis and malignancy.

Authors:  Philip R Cohen; Razelle Kurzrock
Journal:  Clin Dermatol       Date:  2007 May-Jun       Impact factor: 3.541

10.  Sarcoidosis as a benign cause of lymphadenopathy in cancer patients.

Authors:  Ben M Hunt; Eric Vallières; Gordon Buduhan; Ralph Aye; Brian Louie
Journal:  Am J Surg       Date:  2009-03-24       Impact factor: 2.565

View more
  1 in total

1.  The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.

Authors:  Marcos Pantarotto; Rita Barata; Ricardo Coelho; Catarina Carvalheiro; Ines Rolim; Patricia Garrido; Nuno GIl; Filipa Duarte-Ramos; Fernanda S Tonin
Journal:  Cureus       Date:  2022-07-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.